A Phase 3 interventional study of MenACYW conjugate vaccine and MMR in Meningitis, Meningococcal, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 37 sites in 4 countries. Open to participants aged 12 Months to 23 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-05.
Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Meningitis, Meningococcal by Sanofi — none open to participants now, none under way, none of them phase 3. Meningitis, Meningococcal · Sanofi.
Among the 24 studies in Meningitis, Meningococcal by Sanofi, this one is the 8th largest by enrollment of the 23 interventional ones that give a count, is one of 7 that started in 2016, is one of 13 in phase 3, and was the 20th registered.
125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.
Browse Meningitis, Meningococcal studies →None of the 24 studies in Meningitis, Meningococcal by Sanofi is open now. The open studies under Meningitis, Meningococcal, anywhere →
Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 12 Months to 23 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 13 · Phase 4 3
First in 2006; this study’s year is marked. 7 started in 2016.
This study's enrollment of 1,183 is above the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.
Median enrollment 907 across the 23 interventional studies, 100 across the 1 observational. Of the 24 that completed or were terminated, 22 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Sanofi Pasteur, a Sanofi Company, one of the names counted as Sanofi. Under that name alone:
Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.
Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 24 studies in Meningitis, Meningococcal by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This Phase III, open-label, randomized, parallel-group, active-controlled, multicenter study was conducted to assess the immunogenicity and safety of a single dose of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine when administered alone and in combination with other pediatric vaccines in healthy toddlers in South Korea, Thailand, the Russian Federation, and Mexico.
Primary Objective:
Secondary Objective:
Healthy, meningococcal-vaccine naïve toddlers aged 12 to 23 months were randomized either to a single dose of MenACYW Conjugate vaccine alone or in combination with other pediatric vaccines in healthy toddlers in South Korea and Thailand (MMR + varicella vaccine), the Russian Federation (PCV13), and Mexico (DTaP-IPV-HB-Hib). Immunogenicity (pre- and 30 days post-vaccination) and safety was assessed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.
Biological: MenACYW conjugate vaccine · Biological: MMR · Biological: Varicella
Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.
Biological: MenACYW conjugate vaccine
Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.
Biological: MMR · Biological: Varicella
Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine, MMR vaccine, and varicella vaccine on Day 0.
Biological: MenACYW conjugate vaccine · Biological: MMR · Biological: Varicella
Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.
Biological: MenACYW conjugate vaccine
Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MMR vaccine and varicella vaccine on Day 0.
Biological: MMR · Biological: Varicella
Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine and diphtheria, tetanus, acellular pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type-b (DTaP-IPV-HB-Hib) vaccine on Day 0.
Biological: MenACYW conjugate vaccine · Biological: DTaP-IPV-HB-Hib
Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.
Biological: MenACYW conjugate vaccine
Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 23 months) received single dose of DTaP-IPV-HB-Hib vaccine on Day 0.
Biological: DTaP-IPV-HB-Hib
Healthy, meningococcal-vaccine naïve toddlers (aged 15 to 23 months) received single dose of MenACYW Conjugate vaccine and pneumococcal Conjugate vaccine (PCV13) on Day 0.
Biological: MenACYW conjugate vaccine · Biological: PCV13
Healthy, meningococcal-vaccine naïve toddlers (aged 12 to 14 months or 16 to 23 months) received single dose of MenACYW Conjugate vaccine on Day 0.
Biological: MenACYW conjugate vaccine
Healthy, meningococcal-vaccine naïve toddlers (aged 15 to 23 months) received single dose of PCV13 vaccine on Day 0.
Biological: PCV13
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine; 0.5 milliliter (mL), Intramuscular
Measles, Mumps, and Rubella Virus Vaccine Live; 0.5 mL, Subcutaneous
Varicella Virus Vaccine Live; 0.5 mL, Subcutaneous
Diphtheria, Tetanus, Pertussis (acellular component), Hepatitis B, Poliomyelitis (inactivated), and Haemophilus influenzae type-b conjugate vaccine (adsorbed); 0.5 mL, Intramuscular
Pneumococcal 13-valent Conjugate Vaccine; 0.5 mL, Intramuscular
Geometric Mean Titers of Meningococcal Serogroups A, C, Y, and W Antibodies Following Injection With MenACYW Conjugate Vaccine Administered Alone or Concomitantly With Other Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11
Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by serum bactericidal assay using human complement (hSBA) assay. Data for this outcome measure was planned to reported for the combined population of Groups 1 and 10, Groups 2 and 11.
Time frame: Day 0 and Day 30 post-vaccination
Percentage of Participants With Antibody Titers >=1:4 and >=1:8 Against Meningococcal Serogroups A, C, Y, and W Following Injection With MenACYW Conjugate Vaccine Administered Alone or With Other Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11
Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 2 and 11.
Time frame: Day 0 and Day 30 post-vaccination
Percentage of Participants With >=4-Fold Rise in Antibody Titers Against Meningococcal Serogroups A, C, Y, and W Following Injection With MenACYW Conjugate Vaccine Administered Alone or With Other Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11
Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 2 and 11.
Time frame: Day 0 up to Day 30 post-vaccination
Percentage of Participants Achieving hSBA Vaccine Seroresponse for Meningococcal Serogroups A, C, Y, and W Following Injection With MenACYW Conjugate Vaccine Administered Alone or Concomitantly With Pediatric Vaccines: Groups 1, 2, 4, 5, 7, 8, 10, and 11
The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \>=1:16 for participants with pre-vaccination titers \<1:8 or at least a 4-fold increase in post-vaccination hSBA titers from pre- to post-vaccination, for participants with pre-vaccination titers \>=1:8. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 2 and 11.
Time frame: Day 30 post-vaccination
Geometric Mean Titers of MMR-Varicella Antibodies Following Injection With MMR-Varicella Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 1, 3, 10, and 12
Antibodies titers of Measles and Rubella were measured by enzyme immunoassay (EIA). Antibodies titers for mumps and varicella were measured by enzyme-linked immunosorbent assay (ELISA). Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 3 and 12.
Time frame: Day 0 and Day 30 post-vaccination
Percentage of Participants With Immune Response Following Injection With MMR-Varicella Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 1, 3, 10, and 12
Immune response for MMR-Varicella vaccine was defined as: anti-measles Antibody (Ab) concentrations \>=255 milli-international unit per milliliter (mIU/mL), anti-mumps Ab concentrations: \>=10 Ab units/mL, anti-rubella Ab concentrations \>=10 international unit per milliliter (IU/mL),anti-varicella Ab concentrations \>=5 glycoprotein enzyme-linked immunosorbent assay (gpELISA) Ab units/mL. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 3 and 12.
Time frame: Day 0 and Day 30 post-vaccination
Geometric Mean Titers of Pertussis Toxoid (PT) and Filamentous Hemagglutinin (FHA) Antibodies Following Injection With DTaP-IPV-HB-Hib Vaccine Administrated Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6
Antibodies titers of PT and FHA were measured by electrochemiluminescent (ECL) assay.
Time frame: Day 0 and Day 30 post-vaccination
Geometric Mean Titers of DTaP-IPV-HB-Hib Antibodies Following Injection With DTaP-IPV-HB-Hib Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6
Antibodies titers of Diphtheria, Tetanus and Pertussis were measured by ECL assay. Antibodies titers of poliovirus types 1, 2, and 3 were measured by neutralization assay. Antibodies titers of Hepatitis B were measured by an immunodiagnostic system using chemiluminescence detection. Antibodies titers of Polyribosyl-ribitol phosphate (PRP) were measured by Farr-type radioimmunoassay (RIA).
Time frame: Day 0 (for tetanus only) and Day 30 post-vaccination
Percentage of Participants With Immune Response Following Injection With DTaP-IPV-HB-Hib Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6
Immune response for DTaP-IPV-HB-Hib vaccine was defined as: anti-tetanus Ab concentrations: \>= 0.01 and 0.1 IU/mL at Day 0 and \>= 0.1 and 1.0 IU/mL at Day 30, anti-diphtheria Ab concentrations: \>= 0.1 and 1.0 IU/mL, anti-PRP Ab concentrations \>= 0.15 and 1.0 microgram per milliliter (mcg/mL), anti-poliovirus types 1, 2, and 3 Ab titers \>= 1:8, anti-hepatitis B surface antigen Ab concentrations \>= 10 mIU/mL, \>= 100 mIU/mL.
Time frame: Day 0 (tetanus only) and Day 30 post-vaccination
Percentage of Participants With Vaccine Response of PT and FHA Antibodies Following Injection With DTaP-IPV-HB-Hib Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 4 and 6
Pertussis and FHA vaccine response was defined as: if the pre-vaccination concentration is \< 4 \* lower limit of quantification (LLOQ is equal to 2), then the post-vaccination concentration is \>=4 \* pre-vaccination concentration and if the pre-vaccination concentration is \>= 4 \* LLOQ, then the post-vaccination concentration is \>= 2 \* pre-vaccination concentration.
Time frame: Day 0 and Day 30 post-vaccination
Geometric Mean Titers of PCV13 Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F Antibodies Following Injection With PCV13 Vaccine Administrated Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 7 and 9
Antibodies of pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F were measured by ECL assay.
Time frame: Day 0 and Day 30 post-vaccination
Percentage of Participants With Immune Response Following Injection With PCV13 Vaccine Administered Alone or Concomitantly With the MenACYW Conjugate Vaccine: Groups 7 and 9
Immune response for PCV13 for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F was defined as: antibodies concentrations \>=0.35 mcg/mL or \>=1.0 mcg/mL.
Time frame: Day 0 and Day 30 post-vaccination
Number of Participants Reporting at Least One Solicited Injection Site Reactions (Tenderness, Erythema, and Swelling): Groups 1, 2, 3, 10, 11, and 12
Solicited Reaction (SR) was defined as an adverse event (AE) that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions: tenderness, erythema, and swelling. Tenderness: Grade 3: cries when injected limb moved or the movement of the injected limb reduced, Erythema and swelling: Grade 3: \>= 50 millimeter (mm). Participants with any of the Grade and Grade 3 solicited injection-site reactions were reported.
Time frame: Within 7 days post vaccination
Number of Participants Reporting at Least One Solicited Injection Site Reactions (Tenderness, Erythema, and Swelling): Groups 4, 5, and 6
SR was defined as an AE that was prelisted (i.e., solicited) in the eCRF and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions: tenderness, erythema, and swelling. Tenderness: Grade 3: cries when injected limb moved or the movement of the injected limb reduced, Erythema and swelling: Grade 3: \>= 50 mm. Participants with any of the Grade and Grade 3 solicited injection-site reactions were reported.
Time frame: Within 7 days post vaccination
Number of Participants Reporting at Least One Solicited Injection Site Reactions (Tenderness, Erythema, and Swelling): Groups 7, 8, and 9
SR was defined as an AE that was prelisted (i.e., solicited) in the eCRF and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions: tenderness, erythema, and swelling. Tenderness: Grade 3: cries when injected limb moved, or the movement of the injected limb reduced, Erythema and swelling: Grade 3: \>= 50 mm. Participants with any of the Grade and Grade 3 solicited injection-site reactions were reported.
Time frame: Within 7 days post vaccination
Number of Participants Reporting at Least One Solicited Systemic Reactions (Fever, Vomiting, Abnormal Crying, Drowsiness, Appetite Loss, and Irritability)
SR was defined as an AE that was prelisted (i.e., solicited) in the eCRF and considered to be related to vaccination (adverse drug reaction). Solicited systemic reaction: Fever: Grade 3: \> 39.5 degree Celsius, Vomiting: Grade 3: \>= 6 episodes per 24 hours or requiring parenteral hydration, Crying abnormal: Grade 3: \> 3 hours, Drowsiness: Grade 3: sleeping most of the time or difficult to wake up, Appetite lost: Grade 3: refuses \>= 3 feeds/meals or refuses most feeds/meals, Irritability: Grade 3: inconsolable. Participants with any of the Grade and Grade 3 solicited systemic reactions were reported.
Time frame: Within 7 days post vaccination
Study participants were enrolled in South Korea, Mexico, the Russian Federation, and Thailand from 07 November 2016 to 13 June 2018.
| Milestone | South Korea(Group1):MenACYW Conjugate +MMR +Varicella Vaccine | South Korea (Group 2): MenACYW Conjugate Vaccine | South Korea (Group 3): MMR + Varicella Vaccine | Thailand (Group 10):MenACYW Conjugate + MMR+ Varicella Vaccine | Thailand (Group 11): MenACYW Conjugate Vaccine | Thailand (Group 12): MMR + Varicella Vaccine | Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine | Mexico (Group 5): MenACYW Conjugate Vaccine | Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine | Russian Federation (Group7): MenACYW Conjugate + PCV13 Vaccine | Russian Federation (Group 8): MenACYW Conjugate Vaccine | Russian Federation (Group 9): PCV13 Vaccine |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 107 | 53 | 53 | 86 | 42 | 42 | 200 | 100 | 100 | 200 | 100 | 100 |
| Safety analysis set (safas) | 103 | 52 | 53 | 86 | 42 | 42 | 200 | 100 | 100 | 200 | 100 | 99 |
| Per-protocol analysis set (ppas) | 92 | 45 | 50 | 85 | 42 | 42 | 155 | 79 | 68 | 196 | 96 | 92 |
| Completed | 103 | 52 | 53 | 86 | 42 | 42 | 190 | 97 | 95 | 200 | 100 | 99 |
| Not completed | 4 | 1 | 0 | 0 | 0 | 0 | 10 | 3 | 5 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 4 | 1 | 0 | 0 | 0 | 0 | 4 | 0 | 2 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 2 | 3 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by serum bactericidal assay using human complement (hSBA) assay. Data for this outcome measure was planned to reported for the combined population of Groups 1 and 10, Groups 2 and 11.
| titers (1/dilution) | Groups 1and10: MenACYW Conjugate Vaccine+MMR+Varicella Vaccine | Groups 2 and 11: MenACYW Conjugate Vaccine | Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine | Mexico (Group 5): MenACYW Conjugate Vaccine | Russian Federation (Group 7): MenACYW Conjugate +PCV13 Vaccine | Russian Federation (Group 8): MenACYW Conjugate Vaccine |
|---|---|---|---|---|---|---|
| Serogroup A: Day 0 | 5.20 (4.56 to 5.93) | 6.10 (5.00 to 7.44) | 5.35 (4.82 to 5.94) | 5.49 (4.66 to 6.45) | 5.99 (5.30 to 6.76) | 8.54 (6.47 to 11.3) |
| Serogroup A: Day 30 | 43.9 (37.4 to 51.6) | 30.0 (23.1 to 39.0) | 31.4 (25.9 to 38.1) | 37.8 (28.5 to 50.2) | 24.6 (20.2 to 30.1) | 49.0 (36.8 to 65.3) |
| Serogroup C: Day 0 | 2.37 (2.11 to 2.65) | 2.58 (2.15 to 3.10) | 2.21 (2.11 to 2.31) | 2.16 (2.00 to 2.34) | 2.77 (2.43 to 3.16) | 3.69 (2.84 to 4.81) |
| Serogroup C: Day 30 | 876 (725 to 1057) | 600 (456 to 790) | 749 (633 to 886) | 666 (538 to 825) | 205 (156 to 269) | 309 (218 to 437) |
| Serogroup Y: Day 0 | 3.14 (2.78 to 3.54) | 3.12 (2.58 to 3.78) | 2.63 (2.37 to 2.92) | 2.94 (2.45 to 3.53) | 2.90 (2.56 to 3.28) | 3.49 (2.68 to 4.53) |
| Serogroup Y: Day 30 | 88.9 (75.1 to 105) | 60.0 (47.3 to 76.3) | 79.7 (65.7 to 96.6) | 90.9 (66.8 to 124) | 139 (111 to 173) | 172 (130 to 229) |
| Serogroup W: Day 0 | 2.15 (2.00 to 2.30) | 2.31 (2.02 to 2.64) | 2.41 (2.22 to 2.62) | 2.16 (2.04 to 2.30) | 2.93 (2.54 to 3.38) | 3.62 (2.73 to 4.79) |
| Serogroup W: Day 30 | 46.8 (39.1 to 56.0) | 35.5 (27.6 to 45.7) | 40.0 (32.5 to 49.3) | 50.9 (37.2 to 69.8) | 57.4 (47.9 to 68.6) | 57.0 (44.3 to 73.5) |
Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 2 and 11.
| percentage of participants | Groups 1and 10:MenACYW Conjugate Vaccine+MMR+Varicella Vaccine | Groups 2 and 11: MenACYW Conjugate Vaccine | Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine | Mexico (Group 5): MenACYW Conjugate Vaccine | Russian Federation (Group 7): MenACYW Conjugate +PCV13 Vaccine | Russian Federation (Group 8): MenACYW Conjugate Vaccine |
|---|---|---|---|---|---|---|
| Serogroup A: Day 0 (>=1:4) | 75.1 (68.1 to 81.3) | 82.8 (73.2 to 90.0) | 82.6 (75.7 to 88.2) | 82.3 (72.1 to 90.0) | 82.1 (76.1 to 87.2) | 85.4 (76.7 to 91.8) |
| Serogroup A: Day 0 (>=1:8) | 37.9 (30.7 to 45.4) | 44.8 (34.1 to 55.9) | 45.8 (37.8 to 54.0) | 46.8 (35.5 to 58.4) | 49.0 (41.8 to 56.2) | 54.2 (43.7 to 64.4) |
| Serogroup A: Day 30 (>=1:4) | 98.9 (96.0 to 99.9) | 95.4 (88.6 to 98.7) | 98.1 (94.4 to 99.6) | 97.5 (91.2 to 99.7) | 94.9 (90.8 to 97.5) | 97.9 (92.7 to 99.7) |
| Serogroup A: Day 30 (>=1:8) | 97.7 (94.3 to 99.4) | 92.0 (84.1 to 96.7) | 92.9 (87.7 to 96.4) | 89.9 (81.0 to 95.5) | 83.7 (77.7 to 88.6) | 90.6 (82.9 to 95.6) |
| Serogroup C: Day 0 (>=1:4) | 9.6 (5.7 to 14.9) | 16.1 (9.1 to 25.5) | 12.3 (7.5 to 18.5) | 7.6 (2.8 to 15.8) | 19.9 (14.5 to 26.2) | 36.5 (26.9 to 46.9) |
| Serogroup C: Day 0 (>=1:8) | 4.0 (1.6 to 8.0) | 6.9 (2.6 to 14.4) | 1.9 (0.4 to 5.6) | 1.3 (0.0 to 6.9) | 8.7 (5.1 to 13.5) | 17.7 (10.7 to 26.8) |
| Serogroup C: Day 30 (>=1:4) | 100.0 (97.9 to 100.0) | 100.0 (95.8 to 100.0) | 100.0 (97.6 to 100.0) | 100.0 (95.4 to 100.0) | 98.5 (95.6 to 99.7) | 99.0 (94.3 to 100.0) |
| Serogroup C: Day 30 (>=1:8) | 100.0 (97.9 to 100.0) | 100.0 (95.8 to 100.0) | 100.0 (97.6 to 100.0) | 100.0 (95.4 to 100.0) | 93.9 (89.5 to 96.8) | 99.0 (94.3 to 100.0) |
| Serogroup Y: Day 0 (>=1:4) | 32.2 (25.4 to 39.6) | 28.7 (19.5 to 39.4) | 19.4 (13.5 to 26.5) | 25.3 (16.2 to 36.4) | 21.9 (16.4 to 28.4) | 32.3 (23.1 to 42.6) |
| Serogroup Y: Day 0 (>=1:8) | 18.6 (13.2 to 25.2) | 17.2 (10.0 to 26.8) | 11.0 (6.5 to 17.0) | 12.7 (6.2 to 22.0) | 14.3 (9.7 to 20.0) | 15.6 (9.0 to 24.5) |
| Serogroup Y: Day 30 (>=1:4) | 99.4 (96.9 to 100.0) | 96.6 (90.3 to 99.3) | 98.7 (95.4 to 99.8) | 100.0 (95.4 to 100.0) | 98.5 (95.6 to 99.7) | 99.0 (94.3 to 100.0) |
| Serogroup Y: Day 30 (>=1:8) | 99.4 (96.9 to 100.0) | 95.4 (88.6 to 98.7) | 98.7 (95.4 to 99.8) | 98.7 (93.1 to 100.0) | 97.4 (94.1 to 99.2) | 97.9 (92.7 to 99.7) |
| Serogroup W: Day 0 (>=1:4) | 5.1 (2.4 to 9.4) | 11.5 (5.7 to 20.1) | 14.8 (9.6 to 21.4) | 8.9 (3.6 to 17.4) | 16.8 (11.9 to 22.8) | 26.0 (17.6 to 36.0) |
| Serogroup W: Day 0 (>=1:8) | 1.1 (0.1 to 4.0) | 2.3 (0.3 to 8.1) | 7.7 (4.1 to 13.1) | 2.5 (0.3 to 8.8) | 12.8 (8.4 to 18.3) | 20.8 (13.2 to 30.3) |
| Serogroup W: Day 30 (>=1:4) | 98.9 (96.0 to 99.9) | 96.6 (90.3 to 99.3) | 97.4 (93.5 to 99.3) | 96.2 (89.3 to 99.2) | 95.9 (92.1 to 98.2) | 96.9 (91.1 to 99.4) |
| Serogroup W: Day 30 (>=1:8) | 96.0 (92.0 to 98.4) | 92.0 (84.1 to 96.7) | 90.3 (84.5 to 94.5) | 92.4 (84.2 to 97.2) | 94.4 (90.2 to 97.2) | 95.8 (89.7 to 98.9) |
Antibody titers of Meningococcal Serogroups A, C, Y, and W were measured by hSBA assay. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 2 and 11.
| percentage of participants | Groups 1 and10:MenACYW Conjugate Vaccine+MMR+Varicella Vaccine | Groups 2 and 11: MenACYW Conjugate Vaccine | Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine | Mexico (Group 5): MenACYW Conjugate Vaccine | Russian Federation (Group 7): MenACYW Conjugate +PCV13 Vaccine | Russian Federation (Group 8): MenACYW Conjugate Vaccine |
|---|---|---|---|---|---|---|
| Serogroup A | 82.5 (76.1 to 87.8) | 64.4 (53.4 to 74.4) | 69.0 (61.1 to 76.2) | 70.9 (59.6 to 80.6) | 58.2 (50.9 to 65.2) | 72.9 (62.9 to 81.5) |
| Serogroup C | 98.3 (95.1 to 99.6) | 98.9 (93.8 to 100.0) | 100.0 (97.6 to 100.0) | 98.7 (93.1 to 100.0) | 92.3 (87.7 to 95.7) | 91.7 (84.2 to 96.3) |
| Serogroup Y | 95.5 (91.3 to 98.0) | 89.7 (81.3 to 95.2) | 96.8 (92.6 to 98.9) | 94.9 (87.5 to 98.6) | 94.4 (90.2 to 97.2) | 93.8 (86.9 to 97.7) |
| Serogroup W | 94.9 (90.6 to 97.6) | 89.7 (81.3 to 95.2) | 86.5 (80.0 to 91.4) | 92.4 (84.2 to 97.2) | 88.8 (83.5 to 92.8) | 90.6 (82.9 to 95.6) |
The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \>=1:16 for participants with pre-vaccination titers \<1:8 or at least a 4-fold increase in post-vaccination hSBA titers from pre- to post-vaccination, for participants with pre-vaccination titers \>=1:8. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 2 and 11.
| percentage of participants | Groups 1 and10:MenACYW Conjugate Vaccine+MMR+Varicella Vaccine | Groups 2 and 11: MenACYW Conjugate Vaccine | Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine | Mexico (Group 5): MenACYW Conjugate Vaccine | Russian Federation (Group 7): MenACYW Conjugate +PCV13 Vaccine | Russian Federation (Group 8): MenACYW Conjugate Vaccine |
|---|---|---|---|---|---|---|
| Serogroup A | 78.5 (71.7 to 84.3) | 63.2 (52.2 to 73.3) | 67.1 (59.1 to 74.4) | 69.6 (58.2 to 79.5) | 56.1 (48.9 to 63.2) | 71.9 (61.8 to 80.6) |
| Serogroup C | 97.7 (94.3 to 99.4) | 98.9 (93.8 to 100.0) | 100.0 (97.6 to 100) | 98.7 (93.1 to 100.0) | 90.8 (85.9 to 94.5) | 91.7 (84.2 to 96.3) |
| Serogroup Y | 93.2 (88.5 to 96.4) | 88.5 (79.9 to 94.3) | 92.3 (86.9 to 95.9) | 87.3 (78.0 to 93.8) | 92.9 (88.3 to 96.0) | 92.7 (85.6 to 97.0) |
| Serogroup W | 86.4 (80.5 to 91.1) | 83.9 (74.5 to 90.9) | 82.6 (75.7 to 88.2) | 82.3 (72.1 to 90.0) | 82.1 (76.1 to 87.2) | 90.6 (82.9 to 95.6) |
Antibodies titers of Measles and Rubella were measured by enzyme immunoassay (EIA). Antibodies titers for mumps and varicella were measured by enzyme-linked immunosorbent assay (ELISA). Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 3 and 12.
| titers (1/dilution) | Groups 1 and10:MenACYW Conjugate Vaccine+MMR+Varicella Vaccine | Groups 3 and 12: MMR + Varicella Vaccine |
|---|---|---|
| Measles: Day 0 | 40.0 (37.2 to 43.1) | 45.0 (40.1 to 50.4) |
| Measles: Day 30 | 2156 (1893 to 2455) | 2840 (2389 to 3378) |
| Mumps: Day 0 | 5.51 (5.20 to 5.84) | 5.43 (5.05 to 5.83) |
| Mumps: Day 30 | 85.9 (74.7 to 98.7) | 97.6 (83.1 to 115) |
| Rubella: Day 0 | 5.94 (5.32 to 6.63) | 7.12 (6.07 to 8.34) |
| Rubella: Day 30 | 87.6 (79.4 to 96.7) | 104 (91.2 to 118) |
| Varicella: Day 0 | 0.556 (0.484 to 0.638) | 0.665 (0.508 to 0.869) |
| Varicella: Day 30 | 13.4 (11.6 to 15.4) | 17.4 (15.2 to 19.9) |
Immune response for MMR-Varicella vaccine was defined as: anti-measles Antibody (Ab) concentrations \>=255 milli-international unit per milliliter (mIU/mL), anti-mumps Ab concentrations: \>=10 Ab units/mL, anti-rubella Ab concentrations \>=10 international unit per milliliter (IU/mL),anti-varicella Ab concentrations \>=5 glycoprotein enzyme-linked immunosorbent assay (gpELISA) Ab units/mL. Data for this outcome measure was planned to be reported for the combined population of Groups 1 and 10, Groups 3 and 12.
| percentage of participants | Groups 1 and10:MenACYW Conjugate Vaccine+MMR+Varicella Vaccine | Groups 3 and 12: MMR + Varicella Vaccine |
|---|---|---|
| Measles: Day 0 | 0.6 (0.0 to 3.1) | 0.0 (0.0 to 3.9) |
| Measles: Day 30 | 96.6 (92.8 to 98.7) | 97.8 (92.4 to 99.7) |
| Mumps: Day 0 | 7.4 (4.0 to 12.3) | 6.5 (2.4 to 13.7) |
| Mumps: Day 30 | 97.7 (94.3 to 99.4) | 100.0 (96.1 to 100.0) |
| Rubella: Day 0 | 27.3 (20.8 to 34.5) | 31.5 (22.2 to 42.0) |
| Rubella: Day 30 | 100.0 (97.9 to 100) | 100.0 (96.1 to 100) |
| Varicella: Day 0 | 4.0 (1.6 to 8.0) | 7.6 (3.1 to 15.1) |
| Varicella: Day 30 | 93.2 (88.5 to 96.4) | 98.9 (94.1 to 100.0) |
Antibodies titers of PT and FHA were measured by electrochemiluminescent (ECL) assay.
| titers (1/dilution) | Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine | Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine |
|---|---|---|
| PT: Day 0 | 17.9 (15.1 to 21.3) | 20.4 (15.3 to 27.0) |
| PT: Day 30 | 144 (130 to 159) | 169 (144 to 198) |
| FHA: Day 0 | 45.5 (37.0 to 55.9) | 57.4 (41.4 to 79.5) |
| FHA: Day 30 | 299 (265 to 337) | 391 (319 to 480) |
Antibodies titers of Diphtheria, Tetanus and Pertussis were measured by ECL assay. Antibodies titers of poliovirus types 1, 2, and 3 were measured by neutralization assay. Antibodies titers of Hepatitis B were measured by an immunodiagnostic system using chemiluminescence detection. Antibodies titers of Polyribosyl-ribitol phosphate (PRP) were measured by Farr-type radioimmunoassay (RIA).
| titers (1/dilution) | Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine | Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine |
|---|---|---|
| Diphtheria: Day 30 | 5.52 (4.94 to 6.17) | 6.34 (5.51 to 7.30) |
| Tetanus: Day 0 | 0.238 (0.196 to 0.289) | 0.234 (0.177 to 0.309) |
| Tetanus: Day 30 | 7.06 (6.01 to 8.29) | 7.11 (5.79 to 8.74) |
| Polio 1: Day 30 | 4560 (3870 to 5373) | 4034 (3052 to 5332) |
| Polio 2: Day 30 | 7244 (6208 to 8453) | 5618 (4578 to 6895) |
| Polio 3: Day 30 | 5977 (4958 to 7205) | 5100 (3840 to 6772) |
| Hepatitis B: Day 30 | 5171 (4104 to 6515) | 7308 (5135 to 10401) |
| PRP: Day 30 | 46.6 (39.6 to 54.9) | 56.2 (41.5 to 76.1) |
Immune response for DTaP-IPV-HB-Hib vaccine was defined as: anti-tetanus Ab concentrations: \>= 0.01 and 0.1 IU/mL at Day 0 and \>= 0.1 and 1.0 IU/mL at Day 30, anti-diphtheria Ab concentrations: \>= 0.1 and 1.0 IU/mL, anti-PRP Ab concentrations \>= 0.15 and 1.0 microgram per milliliter (mcg/mL), anti-poliovirus types 1, 2, and 3 Ab titers \>= 1:8, anti-hepatitis B surface antigen Ab concentrations \>= 10 mIU/mL, \>= 100 mIU/mL.
| percentage of participants | Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine | Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine |
|---|---|---|
| Diphtheria: Day 30 (>=0.1 IU/mL) | 100.0 (97.6 to 100) | 100.0 (94.7 to 100) |
| Diphtheria: Day 30 (>=1 IU/mL) | 98.7 (95.4 to 99.8) | 100.0 (94.7 to 100) |
| Tetanus: Day 0 (>=0.01 IU/mL) | 100.0 (97.6 to 100) | 100.0 (94.6 to 100) |
| Tetanus: Day 0 (>=0.1 IU/mL) | 81.3 (74.2 to 87.1) | 77.6 (65.8 to 86.9) |
| Tetanus: Day 30 (>=0.1 IU/mL) | 100.0 (97.6 to 100) | 100.0 (94.7 to 100) |
| Tetanus: Day 30 (>=1 IU/mL) | 98.1 (94.4 to 99.6) | 98.5 (92.1 to 100.0) |
| Polio 1: Day 30 (>=8 [1/dilution]) | 100.0 (97.6 to 100) | 100.0 (94.7 to 100) |
| Polio 2: Day 30 (>=8 [1/dilution]) | 100.0 (97.6 to 100) | 100.0 (94.7 to 100) |
| Polio 3: Day 30 (>=8 [1/dilution]) | 100.0 (97.6 to 100) | 100.0 (94.7 to 100) |
| Hepatitis B: Day 30 (>=10 mIU/mL) | 100.0 (97.6 to 100) | 100.0 (94.7 to 100) |
| Hepatitis B: Day 30 (>=100 mIU/mL) | 98.7 (95.4 to 99.8) | 100.0 (94.7 to 100) |
| PRP: Day 30 (>=0.15 mcg/mL) | 100.0 (97.6 to 100) | 100.0 (94.7 to 100) |
| PRP: Day 30 (>=1.0 mcg/mL) | 100.0 (97.6 to 100) | 100.0 (94.7 to 100) |
Pertussis and FHA vaccine response was defined as: if the pre-vaccination concentration is \< 4 \* lower limit of quantification (LLOQ is equal to 2), then the post-vaccination concentration is \>=4 \* pre-vaccination concentration and if the pre-vaccination concentration is \>= 4 \* LLOQ, then the post-vaccination concentration is \>= 2 \* pre-vaccination concentration.
| percentage of participants | Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine | Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine |
|---|---|---|
| PT: Day 30/Day 0 | 91.0 (85.3 to 95.0) | 92.6 (83.7 to 97.6) |
| FHA: Day 30/Day 0 | 89.0 (83.0 to 93.5) | 88.2 (78.1 to 94.8) |
Antibodies of pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F were measured by ECL assay.
| titers (1/dilution) | Russian Federation (Group 7):MenACYW Conjugate + PCV13 Vaccine | Russian Federation (Group 9): PCV13 Vaccine |
|---|---|---|
| Serotype 1: Day 0 | 0.867 (0.741 to 1.01) | 0.918 (0.713 to 1.18) |
| Serotype 1: Day 30 | 2.33 (1.98 to 2.75) | 2.14 (1.63 to 2.81) |
| Serotype 3: Day 0 | 0.409 (0.341 to 0.491) | 0.414 (0.322 to 0.533) |
| Serotype 3: Day 30 | 0.802 (0.664 to 0.967) | 0.773 (0.608 to 0.983) |
| Serotype 4: Day 0 | 0.604 (0.511 to 0.715) | 0.653 (0.507 to 0.840) |
| Serotype 4: Day 30 | 1.97 (1.68 to 2.31) | 1.49 (1.15 to 1.93) |
| Serotype 5: Day 0 | 0.828 (0.719 to 0.953) | 0.782 (0.610 to 1.00) |
| Serotype 5: Day 30 | 1.99 (1.70 to 2.31) | 1.73 (1.33 to 2.24) |
| Serotype 6A: Day 0 | 1.61 (1.33 to 1.95) | 1.48 (1.09 to 2.00) |
| Serotype 6A: Day 30 | 5.96 (4.99 to 7.13) | 6.13 (4.47 to 8.41) |
| Serotype 6B: Day 0 | 0.895 (0.715 to 1.12) | 0.691 (0.514 to 0.929) |
| Serotype 6B: Day 30 | 3.66 (2.99 to 4.50) | 2.57 (1.83 to 3.61) |
| Serotype 7F: Day 0 | 1.32 (1.12 to 1.55) | 1.39 (1.08 to 1.77) |
| Serotype 7F: Day 30 | 3.05 (2.59 to 3.58) | 2.67 (2.05 to 3.47) |
| Serotype 9V: Day 0 | 0.841 (0.710 to 0.997) | 0.863 (0.660 to 1.13) |
| Serotype 9V: Day 30 | 2.34 (1.95 to 2.81) | 2.52 (1.92 to 3.30) |
| Serotype 14: Day 0 | 3.25 (2.74 to 3.86) | 3.00 (2.30 to 3.91) |
| Serotype 14: Day 30 | 7.62 (6.56 to 8.83) | 6.30 (5.00 to 7.93) |
| Serotype 18C: Day 0 | 0.737 (0.620 to 0.876) | 0.995 (0.766 to 1.29) |
| Serotype 18C: Day 30 | 2.19 (1.87 to 2.58) | 2.21 (1.73 to 2.83) |
| Serotype 19A: Day 0 | 1.65 (1.36 to 2.01) | 1.96 (1.46 to 2.64) |
| Serotype 19A: Day 30 | 5.75 (4.85 to 6.80) | 5.91 (4.54 to 7.69) |
| Serotype 19F: Day 0 | 1.78 (1.43 to 2.21) | 1.74 (1.28 to 2.35) |
| Serotype 19F: Day 30 | 5.58 (4.57 to 6.81) | 5.53 (3.98 to 7.69) |
| Serotype 23F: Day 0 | 0.631 (0.519 to 0.768) | 0.733 (0.537 to 1.00) |
| Serotype 23F: Day 30 | 2.42 (2.04 to 2.86) | 2.58 (1.98 to 3.37) |
Immune response for PCV13 for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F was defined as: antibodies concentrations \>=0.35 mcg/mL or \>=1.0 mcg/mL.
| percentage of participants | Russian Federation (Group 7):MenACYW Conjugate + PCV13 Vaccine | Russian Federation (Group 9): PCV13 Vaccine |
|---|---|---|
| Serotype 1: Day 0 (>=0.35 mcg/mL) | 80.8 (74.6 to 86.1) | 79.3 (69.6 to 87.1) |
| Serotype 1: Day 0 (>=1.0 mcg/mL) | 43.0 (35.9 to 50.3) | 45.7 (35.2 to 56.4) |
| Serotype 1: Day 30 (>=0.35 mcg/mL) | 97.4 (94.0 to 99.1) | 94.6 (87.8 to 98.2) |
| Serotype 1: Day 30 (>=1.0 mcg/mL) | 76.4 (69.8 to 82.3) | 70.7 (60.2 to 79.7) |
| Serotype 3: Day 0 (>=0.35 mcg/mL) | 49.2 (42.0 to 56.5) | 53.3 (42.6 to 63.7) |
| Serotype 3: Day 0 (>=1.0 mcg/mL) | 22.3 (16.6 to 28.8) | 18.5 (11.1 to 27.9) |
| Serotype 3: Day 30 (>=0.35 mcg/mL) | 72.3 (65.3 to 78.5) | 76.1 (66.1 to 84.4) |
| Serotype 3: Day 30 (>=1.0 mcg/mL) | 48.2 (40.9 to 55.5) | 38.0 (28.1 to 48.8) |
| Serotype 4: Day 0 (>=0.35 mcg/mL) | 66.8 (59.7 to 73.4) | 68.5 (58.0 to 77.8) |
| Serotype 4: Day 0 (>=1.0 mcg/mL) | 33.7 (27.1 to 40.8) | 38.0 (28.1 to 48.8) |
| Serotype 4: Day 30 (>=0.35 mcg/mL) | 92.7 (88.0 to 95.9) | 90.2 (82.2 to 95.4) |
| Serotype 4: Day 30 (>=1.0 mcg/mL) | 80.1 (73.7 to 85.5) | 62.0 (51.2 to 71.9) |
| Serotype 5: Day 0 (>=0.35 mcg/mL) | 81.3 (75.1 to 86.6) | 76.1 (66.1 to 84.4) |
| Serotype 5: Day 0 (>=1.0 mcg/mL) | 41.5 (34.4 to 48.7) | 50.0 (39.4 to 60.6) |
| Serotype 5: Day 30 (>=0.35 mcg/mL) | 94.8 (90.6 to 97.5) | 90.2 (82.2 to 95.4) |
| Serotype 5: Day 30 (>=1.0 mcg/mL) | 71.2 (64.2 to 77.5) | 69.6 (59.1 to 78.7) |
| Serotype 6A: Day 0 (>=0.35 mcg/mL) | 90.2 (85.1 to 94.0) | 82.6 (73.3 to 89.7) |
| Serotype 6A: Day 0 (>=1.0 mcg/mL) | 63.7 (56.5 to 70.5) | 65.2 (54.6 to 74.9) |
| Serotype 6A: Day 30 (>=0.35 mcg/mL) | 97.4 (94.0 to 99.1) | 96.7 (90.8 to 99.3) |
| Serotype 6A: Day 30 (>=1.0 mcg/mL) | 96.3 (92.6 to 98.5) | 90.2 (82.2 to 95.4) |
| Serotype 6B: Day 0 (>=0.35 mcg/mL) | 72.0 (65.1 to 78.2) | 68.5 (58.0 to 77.8) |
| Serotype 6B: Day 0 (>=1.0 mcg/mL) | 44.6 (37.4 to 51.9) | 41.3 (31.1 to 52.1) |
| Serotype 6B: Day 30 (>=0.35 mcg/mL) | 94.8 (90.6 to 97.5) | 92.4 (84.9 to 96.9) |
| Serotype 6B: Day 30 (>=1.0 mcg/mL) | 86.4 (80.7 to 90.9) | 75.0 (64.9 to 83.4) |
| Serotype 7F: Day 0 (>=0.35 mcg/mL) | 87.0 (81.5 to 91.4) | 88.0 (79.6 to 93.9) |
| Serotype 7F: Day 0 (>=1.0 mcg/mL) | 62.7 (55.5 to 69.5) | 65.2 (54.6 to 74.9) |
| Serotype 7F: Day 30 (>=0.35 mcg/mL) | 98.4 (95.5 to 99.7) | 94.6 (87.8 to 98.2) |
| Serotype 7F: Day 30 (>=1.0 mcg/mL) | 80.1 (73.7 to 85.5) | 83.7 (74.5 to 90.6) |
| Serotype 9V: Day 0 (>=0.35 mcg/mL) | 77.2 (70.6 to 82.9) | 79.3 (69.6 to 87.1) |
| Serotype 9V: Day 0 (>=1.0 mcg/mL) | 42.0 (34.9 to 49.3) | 43.5 (33.2 to 54.2) |
| Serotype 9V: Day 30 (>=0.35 mcg/mL) | 95.3 (91.2 to 97.8) | 92.4 (84.9 to 96.9) |
| Serotype 9V: Day 30 (>=1.0 microg/mL) | 74.3 (67.5 to 80.4) | 75.0 (64.9 to 83.4) |
| Serotype 14: Day 0 (>=0.35 mcg/mL) | 95.8 (92.0 to 98.2) | 92.4 (84.9 to 96.9) |
| Serotype 14: Day 0 (>=1.0 mcg/mL) | 83.3 (77.3 to 88.3) | 87.0 (78.3 to 93.1) |
| Serotype 14: Day 30 (>=0.35 mcg/mL) | 99.0 (96.3 to 99.9) | 98.9 (94.1 to 100.0) |
| Serotype 14: Day 30 (>=1.0 mcg/mL) | 97.4 (94.0 to 99.1) | 94.6 (87.8 to 98.2) |
| Serotype 18C: Day 0 (>=0.35 mcg/mL) | 71.5 (64.6 to 77.8) | 84.8 (75.8 to 91.4) |
| Serotype 18C: Day 0 (>=1.0 mcg/mL) | 40.9 (33.9 to 48.2) | 48.9 (38.3 to 59.6) |
| Serotype 18C: Day 30 (>=0.35 mcg/mL) | 95.3 (91.2 to 97.8) | 92.4 (84.9 to 96.9) |
| Serotype 18C: Day 30 (>=1.0 mcg/mL) | 79.1 (72.6 to 84.6) | 79.3 (69.6 to 87.1) |
| Serotype 19A: Day 0 (>=0.35 mcg/mL) | 87.0 (81.5 to 91.4) | 87.0 (78.3 to 93.1) |
| Serotype 19A: Day 0 (>=1.0 mcg/mL) | 62.7 (55.5 to 69.5) | 69.6 (59.1 to 78.7) |
| Serotype 19A: Day 30 (>=0.35 mcg/mL) | 96.3 (92.6 to 98.5) | 98.9 (94.1 to 100.0) |
| Serotype 19A: Day 30 (>=1.0 mcg/mL) | 92.7 (88.0 to 95.9) | 90.2 (82.2 to 95.4) |
| Serotype 19F: Day 0 (>=0.35 mcg/mL) | 87.0 (81.5 to 91.4) | 89.1 (80.9 to 94.7) |
| Serotype 19F: Day 0 (>=1.0 mcg/mL) | 64.2 (57.0 to 71.0) | 65.2 (54.6 to 74.9) |
| Serotype 19F: Day 30 (>=0.35 mcg/mL) | 96.9 (93.3 to 98.8) | 97.8 (92.4 to 99.7) |
| Serotype 19F: Day 30 (>=1.0 mcg/mL) | 88.0 (82.5 to 92.2) | 85.9 (77.0 to 92.3) |
| Serotype 23F: Day 0 (>=0.35 mcg/mL) | 68.2 (61.1 to 74.7) | 64.1 (53.5 to 73.9) |
| Serotype 23F: Day 0 (>=1.0 mcg/mL) | 34.9 (28.2 to 42.1) | 44.6 (34.2 to 55.3) |
| Serotype 23F: Day 30 (>=0.35 mcg/mL) | 96.3 (92.6 to 98.5) | 93.5 (86.3 to 97.6) |
| Serotype 23F: Day 30 (>=1.0 mcg/mL) | 72.3 (65.3 to 78.5) | 78.3 (68.4 to 86.2) |
Solicited Reaction (SR) was defined as an adverse event (AE) that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions: tenderness, erythema, and swelling. Tenderness: Grade 3: cries when injected limb moved or the movement of the injected limb reduced, Erythema and swelling: Grade 3: \>= 50 millimeter (mm). Participants with any of the Grade and Grade 3 solicited injection-site reactions were reported.
| Participants | South Korea(Group1):MenACYW Conjugate +MMR +Varicella Vaccine | South Korea (Group 2): MenACYW Conjugate Vaccine | South Korea (Group 3): MMR + Varicella Vaccine | Thailand (Group 10):MenACYW Conjugate + MMR +Varicella Vaccine | Thailand (Group 11): MenACYW Conjugate Vaccine | Thailand (Group 12): MMR +Varicella Vaccine |
|---|---|---|---|---|---|---|
| MenACYW: Tenderness: Any Grade | 28 | 15 | — | 29 | 17 | — |
| MenACYW: Tenderness: Grade 3 | 1 | 0 | — | 0 | 1 | — |
| MenACYW: Erythema: Any Grade | 27 | 20 | — | 29 | 13 | — |
| MenACYW: Erythema: Grade 3 | 0 | 2 | — | 0 | 0 | — |
| MenACYW: Swelling: Any Grade | 18 | 14 | — | 15 | 7 | — |
| MenACYW: Swelling: Grade 3 | 0 | 0 | — | 0 | 0 | — |
| MMR: Tenderness: Any Grade | 21 | — | 10 | 17 | — | 18 |
| MMR: Tenderness: Grade 3 | 1 | — | 0 | 0 | — | 0 |
| MMR: Erythema: Any Grade | 13 | — | 6 | 24 | — | 10 |
| MMR: Erythema: Grade 3 | 0 | — | 0 | 0 | — | 0 |
| MMR: Swelling: Any Grade | 7 | — | 1 | 11 | — | 4 |
| MMR: Swelling: Grade 3 | 0 | — | 0 | 0 | — | 0 |
| Varicella: Tenderness: Any Grade | 23 | — | 11 | 17 | — | 14 |
| Varicella: Tenderness: Grade 3 | 0 | — | 0 | 0 | — | 1 |
| Varicella: Erythema: Any Grade | 19 | — | 4 | 18 | — | 13 |
| Varicella: Erythema: Grade 3 | 1 | — | 0 | 0 | — | 0 |
| Varicella: Swelling: Any Grade | 10 | — | 2 | 12 | — | 5 |
| Varicella: Swelling: Grade 3 | 0 | — | 0 | 0 | — | 0 |
SR was defined as an AE that was prelisted (i.e., solicited) in the eCRF and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions: tenderness, erythema, and swelling. Tenderness: Grade 3: cries when injected limb moved or the movement of the injected limb reduced, Erythema and swelling: Grade 3: \>= 50 mm. Participants with any of the Grade and Grade 3 solicited injection-site reactions were reported.
| Participants | Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine | Mexico (Group 5): MenACYW Conjugate Vaccine | Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine |
|---|---|---|---|
| MenACYW: Tenderness: Any Grade | 68 | 27 | — |
| MenACYW: Tenderness: Grade 3 | 6 | 1 | — |
| MenACYW: Erythema: Any Grade | 40 | 15 | — |
| MenACYW: Erythema: Grade 3 | 3 | 3 | — |
| MenACYW: Swelling: Any Grade | 23 | 8 | — |
| MenACYW: Swelling: Grade 3 | 2 | 2 | — |
| DTaP-IPV-HB-Hib: Tenderness: Any Grade | 80 | — | 54 |
| DTaP-IPV-HB-Hib: Tenderness: Grade 3 | 6 | — | 10 |
| DTaP-IPV-HB-Hib: Erythema: Any Grade | 56 | — | 37 |
| DTaP-IPV-HB-Hib: Erythema: Grade 3 | 8 | — | 5 |
| DTaP-IPV-HB-Hib: Swelling: Any Grade | 45 | — | 30 |
| DTaP-IPV-HB-Hib: Swelling: Grade 3 | 8 | — | 4 |
SR was defined as an AE that was prelisted (i.e., solicited) in the eCRF and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions: tenderness, erythema, and swelling. Tenderness: Grade 3: cries when injected limb moved, or the movement of the injected limb reduced, Erythema and swelling: Grade 3: \>= 50 mm. Participants with any of the Grade and Grade 3 solicited injection-site reactions were reported.
| Participants | Russian Federation (Group 7):MenACYW Conjugate + PCV13 Vaccine | Russian Federation (Group 8): MenACYW Conjugate Vaccine | Russian Federation (Group 9): PCV13 Vaccine |
|---|---|---|---|
| MenACYW: Tenderness: Any Grade | 28 | 8 | — |
| MenACYW: Tenderness: Grade 3 | 4 | 0 | — |
| MenACYW: Erythema: Any Grade | 43 | 17 | — |
| MenACYW: Erythema: Grade 3 | 0 | 0 | — |
| MenACYW: Swelling: Any Grade | 8 | 7 | — |
| MenACYW: Swelling: Grade 3 | 0 | 0 | — |
| PCV13: Tenderness: Any Grade | 34 | — | 9 |
| PCV13: Tenderness: Grade 3 | 5 | — | 1 |
| PCV13: Erythema: Any Grade | 48 | — | 8 |
| PCV13: Erythema: Grade 3 | 0 | — | 0 |
| PCV13: Swelling: Any Grade | 19 | — | 2 |
| PCV13: Swelling: Grade 3 | 0 | — | 0 |
SR was defined as an AE that was prelisted (i.e., solicited) in the eCRF and considered to be related to vaccination (adverse drug reaction). Solicited systemic reaction: Fever: Grade 3: \> 39.5 degree Celsius, Vomiting: Grade 3: \>= 6 episodes per 24 hours or requiring parenteral hydration, Crying abnormal: Grade 3: \> 3 hours, Drowsiness: Grade 3: sleeping most of the time or difficult to wake up, Appetite lost: Grade 3: refuses \>= 3 feeds/meals or refuses most feeds/meals, Irritability: Grade 3: inconsolable. Participants with any of the Grade and Grade 3 solicited systemic reactions were reported.
| Participants | South Korea(Group1):MenACYW Conjugate +MMR +Varicella Vaccine | South Korea (Group 2): MenACYW Conjugate Vaccine | South Korea (Group 3): MMR + Varicella Vaccine | Thailand (Group 10):MenACYW Conjugate + MMR +Varicella Vaccine | Thailand (Group 11): MenACYW Conjugate Vaccine | Thailand (Group 12): MMR + Varicella Vaccine | Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine | Mexico (Group 5): MenACYW Conjugate Vaccine | Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine | Russian Federation (Group7): MenACYW Conjugate + PCV13 Vaccine | Russian Federation (Group 8): MenACYW Conjugate Vaccine | Russian Federation (Group 9): PCV13 Vaccine |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fever: Any Grade | 17 | 9 | 5 | 6 | 1 | 3 | 32 | 7 | 16 | 12 | 3 | 2 |
| Fever: Grade 3 | 1 | 2 | 1 | 0 | 1 | 0 | 4 | 1 | 0 | 0 | 0 | 0 |
| Vomiting: Any Grade | 6 | 3 | 2 | 5 | 4 | 5 | 15 | 6 | 9 | 0 | 0 | 0 |
| Vomiting: Grade 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Abnormal crying: Any Grade | 21 | 9 | 6 | 14 | 17 | 12 | 46 | 25 | 26 | 8 | 4 | 2 |
| Abnormal crying: Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 0 | 0 |
| Drowsiness: Any Grade | 17 | 8 | 9 | 8 | 7 | 7 | 31 | 15 | 17 | 25 | 6 | 4 |
| Drowsiness: Grade 3 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 1 | 0 | 0 |
| Appetite Lost: Any Grade | 29 | 10 | 8 | 11 | 12 | 5 | 51 | 25 | 20 | 19 | 12 | 7 |
| Appetite Lost: Grade 3 | 1 | 0 | 0 | 0 | 0 | 2 | 8 | 2 | 3 | 1 | 0 | 0 |
| Irritability: Any Grade | 31 | 12 | 11 | 14 | 11 | 14 | 64 | 34 | 33 | 26 | 16 | 9 |
| Irritability: Grade 3 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | 1 | 3 | 4 | 0 | 0 |
Collected over AE data were collected from Day 0 up to Day 30 post-vaccination. SR data were collected within 7 days after vaccination. Serious adverse event (SAE) data were collected throughout the study period (up to Day 30 post-vaccination).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| South Korea(Group1):MenACYW Conjugate +MMR +Varicella Vaccine | 0/103 (0%) | 6/103 (5.8%) | 85/103 (82.5%) |
| South Korea (Group 2): MenACYW Conjugate Vaccine | 0/52 (0%) | 4/52 (7.7%) | 43/52 (82.7%) |
| South Korea (Group 3): MMR + Varicella Vaccine | 0/53 (0%) | 2/53 (3.8%) | 37/53 (69.8%) |
| Thailand (Group 10):MenACYW Conjugate + MMR +Varicella Vaccine | 0/86 (0%) | 0/86 (0%) | 58/86 (67.4%) |
| Thailand (Group 11): MenACYW Conjugate Vaccine | 0/42 (0%) | 1/42 (2.4%) | 37/42 (88.1%) |
| Thailand (Group 12): MMR + Varicella Vaccine | 0/42 (0%) | 0/42 (0%) | 37/42 (88.1%) |
| Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine | 0/200 (0%) | 0/200 (0%) | 142/200 (71%) |
| Mexico (Group 5): MenACYW Conjugate Vaccine | 0/100 (0%) | 0/100 (0%) | 65/100 (65%) |
| Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine | 0/100 (0%) | 1/100 (1%) | 85/100 (85%) |
| Russian Federation (Group 7):MenACYW Conjugate + PCV13 Vaccine | 0/200 (0%) | 0/200 (0%) | 75/200 (37.5%) |
| Russian Federation (Group 8): MenACYW Conjugate Vaccine | 0/100 (0%) | 0/100 (0%) | 30/100 (30%) |
| Russian Federation (Group 9): PCV13 Vaccine | 0/99 (0%) | 0/99 (0%) | 17/99 (17.2%) |
| Event | South Korea(Group1):MenACYW Conjugate +MMR +Varicella Vaccine | South Korea (Group 2): MenACYW Conjugate Vaccine | South Korea (Group 3): MMR + Varicella Vaccine | Thailand (Group 10):MenACYW Conjugate + MMR +Varicella Vaccine | Thailand (Group 11): MenACYW Conjugate Vaccine | Thailand (Group 12): MMR + Varicella Vaccine | Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine | Mexico (Group 5): MenACYW Conjugate Vaccine | Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine | Russian Federation (Group 7):MenACYW Conjugate + PCV13 Vaccine | Russian Federation (Group 8): MenACYW Conjugate Vaccine | Russian Federation (Group 9): PCV13 Vaccine |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BronchiolitisInfections and infestations | 0/103 | 2/52 | 0/53 | 0/86 | 0/42 | 0/42 | 0/200 | 0/100 | 0/100 | 0/200 | 0/100 | 0/99 |
| Croup InfectiousInfections and infestations | 0/103 | 0/52 | 0/53 | 0/86 | 1/42 | 0/42 | 0/200 | 0/100 | 0/100 | 0/200 | 0/100 | 0/99 |
| Bronchitis ViralInfections and infestations | 2/103 | 0/52 | 0/53 | 0/86 | 0/42 | 0/42 | 0/200 | 0/100 | 0/100 | 0/200 | 0/100 | 0/99 |
| BronchitisInfections and infestations | 0/103 | 1/52 | 0/53 | 0/86 | 0/42 | 0/42 | 0/200 | 0/100 | 0/100 | 0/200 | 0/100 | 0/99 |
| GastroenteritisInfections and infestations | 1/103 | 1/52 | 0/53 | 0/86 | 0/42 | 0/42 | 0/200 | 0/100 | 0/100 | 0/200 | 0/100 | 0/99 |
| Hand-Foot-And-Mouth DiseaseInfections and infestations | 1/103 | 1/52 | 0/53 | 0/86 | 0/42 | 0/42 | 0/200 | 0/100 | 0/100 | 0/200 | 0/100 | 0/99 |
| Otitis Media ViralInfections and infestations | 0/103 | 0/52 | 1/53 | 0/86 | 0/42 | 0/42 | 0/200 | 0/100 | 0/100 | 0/200 | 0/100 | 0/99 |
| Pneumonia ViralInfections and infestations | 0/103 | 0/52 | 1/53 | 0/86 | 0/42 | 0/42 | 0/200 | 0/100 | 0/100 | 0/200 | 0/100 | 0/99 |
| Febrile ConvulsionNervous system disorders | 0/103 | 0/52 | 0/53 | 0/86 | 0/42 | 0/42 | 0/200 | 0/100 | 1/100 | 0/200 | 0/100 | 0/99 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/103 | 0/52 | 0/53 | 0/86 | 0/42 | 0/42 | 0/200 | 0/100 | 1/100 | 0/200 | 0/100 | 0/99 |
| Event | South Korea(Group1):MenACYW Conjugate +MMR +Varicella Vaccine | South Korea (Group 2): MenACYW Conjugate Vaccine | South Korea (Group 3): MMR + Varicella Vaccine | Thailand (Group 10):MenACYW Conjugate + MMR +Varicella Vaccine | Thailand (Group 11): MenACYW Conjugate Vaccine | Thailand (Group 12): MMR + Varicella Vaccine | Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine | Mexico (Group 5): MenACYW Conjugate Vaccine | Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine | Russian Federation (Group 7):MenACYW Conjugate + PCV13 Vaccine | Russian Federation (Group 8): MenACYW Conjugate Vaccine | Russian Federation (Group 9): PCV13 Vaccine |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Injection Site PainGeneral disorders | 31/103 | 15/52 | 12/53 | 31/86 | 17/42 | 19/42 | 87/200 | 27/100 | 54/100 | 37/200 | 8/100 | 9/99 |
| Injection Site ErythemaGeneral disorders | 35/103 | 20/52 | 8/53 | 36/86 | 13/42 | 16/42 | 67/200 | 15/100 | 37/100 | 55/200 | 17/100 | 8/99 |
| CryingGeneral disorders | 21/103 | 9/52 | 6/53 | 15/86 | 17/42 | 12/42 | 46/200 | 25/100 | 26/100 | 8/200 | 4/100 | 2/99 |
| IrritabilityPsychiatric disorders | 31/103 | 12/52 | 11/53 | 14/86 | 11/42 | 14/42 | 64/200 | 34/100 | 33/100 | 26/200 | 16/100 | 9/99 |
| NasopharyngitisInfections and infestations | 29/103 | 17/52 | 13/53 | 5/86 | 3/42 | 6/42 | 29/200 | 18/100 | 15/100 | 2/200 | 1/100 | 0/99 |
| Injection Site SwellingGeneral disorders | 25/103 | 14/52 | 3/53 | 18/86 | 7/42 | 5/42 | 52/200 | 8/100 | 30/100 | 21/200 | 7/100 | 2/99 |
| Decreased AppetiteMetabolism and nutrition disorders | 29/103 | 10/52 | 8/53 | 11/86 | 12/42 | 5/42 | 51/200 | 25/100 | 20/100 | 19/200 | 12/100 | 7/99 |
| PyrexiaGeneral disorders | 21/103 | 11/52 | 10/53 | 6/86 | 3/42 | 4/42 | 35/200 | 8/100 | 17/100 | 13/200 | 3/100 | 2/99 |
| SomnolenceNervous system disorders | 17/103 | 8/52 | 9/53 | 8/86 | 7/42 | 7/42 | 31/200 | 15/100 | 17/100 | 25/200 | 6/100 | 4/99 |
| VomitingGastrointestinal disorders | 7/103 | 3/52 | 2/53 | 6/86 | 4/42 | 6/42 | 16/200 | 7/100 | 9/100 | 0/200 | 0/100 | 0/99 |
Analysis was performed on all randomized participants.
| Age, Continuous(months) | South Korea(Group1):MenACYW Conjugate +MMR+ Varicella Vaccine | South Korea (Group 2): MenACYW Conjugate Vaccine | South Korea (Group 3): MMR + Varicella Vaccine | Thailand (Group 10): MenACYW Conjugate + MMR+Varicella Vaccine | Thailand (Group 11): MenACYW Conjugate Vaccine | Thailand (Group 12): MMR + Varicella Vaccine | Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine | Mexico (Group 5): MenACYW Conjugate Vaccine | Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine | Russian Federation (Group7): MenACYW Conjugate + PCV13 Vaccine | Russian Federation (Group 8): MenACYW Conjugate Vaccine | Russian Federation (Group 9): PCV13 Vaccine | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 12.7 ± 1.58 | 12.7 ± 1.50 | 12.3 ± 0.96 | 12.4 ± 0.90 | 12.4 ± 0.88 | 12.8 ± 1.76 | 16.4 ± 2.73 | 16.8 ± 2.83 | 16.8 ± 2.99 | 16.5 ± 2.36 | 16.0 ± 3.10 | 16.3 ± 2.26 | 15.2 ± 2.97 |
| Sex: Female, Male(Participants) | South Korea(Group1):MenACYW Conjugate +MMR+ Varicella Vaccine | South Korea (Group 2): MenACYW Conjugate Vaccine | South Korea (Group 3): MMR + Varicella Vaccine | Thailand (Group 10): MenACYW Conjugate + MMR+Varicella Vaccine | Thailand (Group 11): MenACYW Conjugate Vaccine | Thailand (Group 12): MMR + Varicella Vaccine | Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine | Mexico (Group 5): MenACYW Conjugate Vaccine | Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine | Russian Federation (Group7): MenACYW Conjugate + PCV13 Vaccine | Russian Federation (Group 8): MenACYW Conjugate Vaccine | Russian Federation (Group 9): PCV13 Vaccine | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 49 | 18 | 29 | 47 | 23 | 23 | 93 | 46 | 48 | 78 | 51 | 45 | 550 |
| Male | 58 | 35 | 24 | 39 | 19 | 19 | 107 | 54 | 52 | 122 | 49 | 55 | 633 |
| Race (NIH/OMB)(Participants) | South Korea(Group1):MenACYW Conjugate +MMR+ Varicella Vaccine | South Korea (Group 2): MenACYW Conjugate Vaccine | South Korea (Group 3): MMR + Varicella Vaccine | Thailand (Group 10): MenACYW Conjugate + MMR+Varicella Vaccine | Thailand (Group 11): MenACYW Conjugate Vaccine | Thailand (Group 12): MMR + Varicella Vaccine | Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine | Mexico (Group 5): MenACYW Conjugate Vaccine | Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine | Russian Federation (Group7): MenACYW Conjugate + PCV13 Vaccine | Russian Federation (Group 8): MenACYW Conjugate Vaccine | Russian Federation (Group 9): PCV13 Vaccine | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 86 | 42 | 42 | 0 | 0 | 1 | 2 | 1 | 4 | 179 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 | 0 | 200 | 100 | 99 | 198 | 99 | 96 | 792 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 106 | 53 | 53 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 212 |
| Region of Enrollment(Participants) | South Korea(Group1):MenACYW Conjugate +MMR+ Varicella Vaccine | South Korea (Group 2): MenACYW Conjugate Vaccine | South Korea (Group 3): MMR + Varicella Vaccine | Thailand (Group 10): MenACYW Conjugate + MMR+Varicella Vaccine | Thailand (Group 11): MenACYW Conjugate Vaccine | Thailand (Group 12): MMR + Varicella Vaccine | Mexico (Group 4): MenACYW Conjugate + DTaP-IPV-HB-Hib Vaccine | Mexico (Group 5): MenACYW Conjugate Vaccine | Mexico (Group 6): DTaP-IPV-HB-Hib Vaccine | Russian Federation (Group7): MenACYW Conjugate + PCV13 Vaccine | Russian Federation (Group 8): MenACYW Conjugate Vaccine | Russian Federation (Group 9): PCV13 Vaccine | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| South Korea | 107 | 53 | 53 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 213 |
| Mexico | 0 | 0 | 0 | 0 | 0 | 0 | 200 | 100 | 100 | 0 | 0 | 0 | 400 |
| Russia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 200 | 100 | 100 | 400 |
| Thailand | 0 | 0 | 0 | 86 | 42 | 42 | 0 | 0 | 0 | 0 | 0 | 0 | 170 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Nov 2016 to primary completion in Jul 2018, 20 months.
Results were first posted in Jun 2020, 1 year 10 months after primary completion. A results delay was requested in Jul 2019.
Of 25 phase 3 interventional studies under Meningitis, Meningococcal, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 20. This study's 20 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Measles-Mumps-Rubella Vaccine · 13-valent pneumococcal vaccine
Sanofi Pasteur, a Sanofi Company →